RISK FACTORS FOR HYPERSENSITIVITY REACTIONS (HSRS) AMONG OVARIAN CANCER (EOC) PATIENTS TREATED WITH CARBOPLATIN-BASED CHEMOTHERAPY

被引：0
|
作者：
Jerzak, K. [1 ]
Manshadi, S. Deghan [1 ]
Ng, P. [2 ]
Maganti, M. [2 ]
McCuaig, J. M. [2 ]
Oza, A. [2 ]
Mackay, H. [2 ]
机构：
[1] Univ Toronto, Toronto, ON, Canada
[2] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2014年 / 24卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IGCSM-0974
引用
收藏
页码：331 / 332
页数：2
相关论文
共 50 条
  • [21] Efficacy of carboplatin-based chemotherapy regimens in patients with bladder cancer in the neoadjuvant setting.
    Aslam, Hafiz
    Bukhari, Sumera
    Nadeem, Muhammad
    Awwal, Talha
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [22] Safety and Efficacy of Weekly Paclitaxel and Cisplatin Chemotherapy for Ovarian Cancer Patients with Hypersensitivity to Carboplatin
    Tate, Shinichi
    Nishikimi, Kyoko
    Matsuoka, Ayumu
    Otsuka, Satoyo
    Shozu, Makio
    CANCERS, 2021, 13 (04) : 1 - 11
  • [23] Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy
    Sendo, T
    Sakai, N
    Itoh, Y
    Ikesue, H
    Kobayashi, H
    Hirakawa, T
    Nakano, H
    Oishi, R
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 56 (01) : 91 - 96
  • [24] Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy
    Toshiaki Sendo
    Naoko Sakai
    Yoshinori Itoh
    Hiroaki Ikesue
    Hiroaki Kobayashi
    Toshio Hirakawa
    Hitoo Nakano
    Ryozo Oishi
    Cancer Chemotherapy and Pharmacology, 2005, 56 : 91 - 96
  • [25] Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery
    Bae, Jeong Hoon
    Lee, Joon Mo
    Ryu, Ki Sung
    Lee, Yong Seok
    Park, Yong Gyu
    Hur, Soo Young
    Ahn, Woong Shik
    Namkoong, Seong Eun
    GYNECOLOGIC ONCOLOGY, 2007, 106 (01) : 193 - 200
  • [26] The impact of prophylactic prolonged carboplatin infusion on risk of hypersensitivity reactions during carboplatin retreatment in epithelial ovarian cancer
    O'Cearbhaill, R.
    Zhou, Q.
    Sabbatini, P.
    EJC SUPPLEMENTS, 2009, 7 (02): : 465 - 465
  • [27] Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer
    Gadducci, A.
    Tana, R.
    Teti, G.
    Zanca, G.
    Fanucchi, A.
    Genazzani, A. R.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2008, 18 (04) : 615 - 620
  • [28] RESPONSE TO 2ND-LINE WEEKLY CISPLATIN CHEMOTHERAPY IN OVARIAN-CANCER PREVIOUSLY TREATED WITH A CISPLATIN-BASED OR CARBOPLATIN-BASED REGIMEN
    BOLIS, G
    SCARFONE, G
    LUCHINI, L
    FERRARIS, C
    ZANABONI, F
    PRESTI, M
    GIARDINA, G
    VILLA, A
    PARAZZINI, F
    EUROPEAN JOURNAL OF CANCER, 1994, 30A (12) : 1764 - 1768
  • [29] The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy
    Xia Wu
    Qin-Mei Feng
    Ying Wang
    Jun Shi
    Hai-Liang Ge
    Wen Di
    Cancer Immunology, Immunotherapy, 2010, 59 : 279 - 291
  • [30] Audit of Hypersensitivity Reactions (HSRs) of Patients with Breast Cancer being Treated with Nab-paclitaxel after Severe HSR to Prior Taxane Chemotherapy; is it Safe?
    Jaschke, M.
    Ren, X.
    Michie, C.
    CLINICAL ONCOLOGY, 2024, 36 (04) : E107 - E107
12345